Company / Current Liabilities
Inhibikase Therapeutics, Inc. Current Liabilities History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$3.7M
FY2024
5-year range
$3.4M / $4.1M
FY2021-FY2024
Trend
+8.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities returned to growth in FY2024 after 2 years of decline, reaching $4M.
Based on SEC 10-K filings.
$4M in FY2024 with a 3-year CAGR of -2.7%.
Remained stable around $4M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -2.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -2.7%, indicating a declining trend.
- In FY2024, current liabilities increased 8.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.7M | +8.6% |
| FY2023 | $3.4M | -7.0% |
| FY2022 | $3.7M | -8.9% |
| FY2021 | $4.1M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026